Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1992 Aug 1;89(15):7095–7099. doi: 10.1073/pnas.89.15.7095

Dopamine transporter mRNA content in human substantia nigra decreases precipitously with age.

M J Bannon 1, M S Poosch 1, Y Xia 1, D J Goebel 1, B Cassin 1, G Kapatos 1
PMCID: PMC49652  PMID: 1353885

Abstract

The dopamine transporter is the primary means of inactivating synaptic dopamine as well as a major site of action for psychostimulants (such as cocaine and amphetamine) and for neurotoxins that induce parkinsonism. In the present study, a human dopamine transporter partial cDNA clone obtained by polymerase chain reaction exhibited 87% and 89% identity at the nucleic acid and amino acid levels, respectively, with transmembrane domains 3-5 of the rat homolog. This clone was used to quantitate human dopamine transporter mRNA by nuclease protection assay. The postmortem content of dopamine transporter mRNA in the substantia nigrae of 18- to 57-yr-old subjects was relatively constant, while in subjects greater than 57 yr old, a precipitous (greater than 95%) decline in substantia nigra dopamine transporter mRNA was evident. In contrast, tyrosine hydroxylase mRNA in the same samples declined in a linear manner with increasing age. In situ hybridization experiments confirmed the profound loss of dopamine transporter gene expression in melanin-positive (presumptive dopamine) nigral neurons. These data may begin to shed light on compensatory changes occurring in human dopamine neurons during normal aging.

Full text

PDF
7095

Images in this article

7096Image
on p.7096
7098Image
on p.7098

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bannon M. J., Poosch M. S., Haverstick D. M., Mandal A., Xue I. C., Shibata K., Dragovic L. J. Preprotachykinin gene expression in the human basal ganglia: characterization of mRNAs and pre-mRNAs produced by alternate RNA splicing. Brain Res Mol Brain Res. 1992 Jan;12(1-3):225–231. doi: 10.1016/0169-328x(92)90088-s. [DOI] [PubMed] [Google Scholar]
  2. Bannon M. J., Xue C. H., Shibata K., Dragovic L. J., Kapatos G. Expression of a human cocaine-sensitive dopamine transporter in Xenopus laevis oocytes. J Neurochem. 1990 Feb;54(2):706–708. doi: 10.1111/j.1471-4159.1990.tb01929.x. [DOI] [PubMed] [Google Scholar]
  3. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  4. Clark A. N., Mankikar G. D. d-Amphetamine in elderly patients refractory to rehabilitation procedures. J Am Geriatr Soc. 1979 Apr;27(4):174–177. doi: 10.1111/j.1532-5415.1979.tb06442.x. [DOI] [PubMed] [Google Scholar]
  5. Coker G. T., 3rd, Studelska D., Harmon S., Burke W., O'Malley K. L. Analysis of tyrosine hydroxylase and insulin transcripts in human neuroendocrine tissues. Brain Res Mol Brain Res. 1990 Jul;8(2):93–98. doi: 10.1016/0169-328x(90)90052-f. [DOI] [PubMed] [Google Scholar]
  6. Crook T., Ferris S., Sathananthan G., Raskin A., Gershon S. The effect of methylphenidate on test performance in the cognitively impaired aged. Psychopharmacology (Berl) 1977 May 9;52(3):251–255. doi: 10.1007/BF00426708. [DOI] [PubMed] [Google Scholar]
  7. DARVILL F. T., Jr, WOOLLEY S. Double blind evaluation of methylphenidate (ritalin) hydrochloride; its use in the management of institutionalized geriatric patients. J Am Med Assoc. 1959 Apr 11;169(15):1739–1741. doi: 10.1001/jama.1959.03000320041011. [DOI] [PubMed] [Google Scholar]
  8. De Keyser J., Ebinger G., Vauquelin G. Age-related changes in the human nigrostriatal dopaminergic system. Ann Neurol. 1990 Feb;27(2):157–161. doi: 10.1002/ana.410270210. [DOI] [PubMed] [Google Scholar]
  9. German D. C., Dubach M., Askari S., Speciale S. G., Bowden D. M. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian syndrome in Macaca fascicularis: which midbrain dopaminergic neurons are lost? Neuroscience. 1988 Jan;24(1):161–174. doi: 10.1016/0306-4522(88)90320-x. [DOI] [PubMed] [Google Scholar]
  10. German D. C., Manaye K., Smith W. K., Woodward D. J., Saper C. B. Midbrain dopaminergic cell loss in Parkinson's disease: computer visualization. Ann Neurol. 1989 Oct;26(4):507–514. doi: 10.1002/ana.410260403. [DOI] [PubMed] [Google Scholar]
  11. Gershon S., Crook T., Ferris S., Reisberg B. Psychostimulants and neuropeptides in geropsychiatry [proceedings]. Psychopharmacol Bull. 1980 Oct;16(4):31–34. [PubMed] [Google Scholar]
  12. Gilbert J. G., Donnelly K. J., Zimmer L. E., Kubis J. F. Effect of magnesium pemoline and methylphenidate on memory improvement and mood in normal aging subjects. Int J Aging Hum Dev. 1973 Winter;4(1):35–51. doi: 10.2190/AT8V-BRFY-DLUP-B0HH. [DOI] [PubMed] [Google Scholar]
  13. Graybiel A. M., Moratalla R. Dopamine uptake sites in the striatum are distributed differentially in striosome and matrix compartments. Proc Natl Acad Sci U S A. 1989 Nov;86(22):9020–9024. doi: 10.1073/pnas.86.22.9020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Halliday R., Callaway E., Naylor H., Gratzinger P., Prael R. The effects of stimulant drugs on information processing in elderly adults. J Gerontol. 1986 Nov;41(6):748–757. doi: 10.1093/geronj/41.6.748. [DOI] [PubMed] [Google Scholar]
  15. Haverstick D. M., Jeziorski M., Bannon M. J. Developmental profile of striatal preprotachykinin gene expression. J Neurochem. 1990 Sep;55(3):764–768. doi: 10.1111/j.1471-4159.1990.tb04557.x. [DOI] [PubMed] [Google Scholar]
  16. Hirsch E., Graybiel A. M., Agid Y. A. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature. 1988 Jul 28;334(6180):345–348. doi: 10.1038/334345a0. [DOI] [PubMed] [Google Scholar]
  17. Javoy-Agid F., Hirsch E. C., Dumas S., Duyckaerts C., Mallet J., Agid Y. Decreased tyrosine hydroxylase messenger RNA in the surviving dopamine neurons of the substantia nigra in Parkinson's disease: an in situ hybridization study. Neuroscience. 1990;38(1):245–253. doi: 10.1016/0306-4522(90)90389-l. [DOI] [PubMed] [Google Scholar]
  18. Johnson S. A., Morgan D. G., Finch C. E. Extensive postmortem stability of RNA from rat and human brain. J Neurosci Res. 1986;16(1):267–280. doi: 10.1002/jnr.490160123. [DOI] [PubMed] [Google Scholar]
  19. Kilty J. E., Lorang D., Amara S. G. Cloning and expression of a cocaine-sensitive rat dopamine transporter. Science. 1991 Oct 25;254(5031):578–579. doi: 10.1126/science.1948035. [DOI] [PubMed] [Google Scholar]
  20. Kleiman R., Banker G., Steward O. Differential subcellular localization of particular mRNAs in hippocampal neurons in culture. Neuron. 1990 Dec;5(6):821–830. doi: 10.1016/0896-6273(90)90341-c. [DOI] [PubMed] [Google Scholar]
  21. Koller W., O'Hara R., Weiner W., Lang A., Nutt J., Agid Y., Bonnet A. M., Jankovic J. Relationship of aging to Parkinson's disease. Adv Neurol. 1987;45:317–321. [PubMed] [Google Scholar]
  22. Mayer R. A., Kindt M. V., Heikkila R. E. Prevention of the nigrostriatal toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by inhibitors of 3,4-dihydroxyphenylethylamine transport. J Neurochem. 1986 Oct;47(4):1073–1079. doi: 10.1111/j.1471-4159.1986.tb00722.x. [DOI] [PubMed] [Google Scholar]
  23. McGeer P. L., Itagaki S., Akiyama H., McGeer E. G. Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol. 1988 Oct;24(4):574–576. doi: 10.1002/ana.410240415. [DOI] [PubMed] [Google Scholar]
  24. McGeer P. L., McGeer E. G., Suzuki J. S. Aging and extrapyramidal function. Arch Neurol. 1977 Jan;34(1):33–35. doi: 10.1001/archneur.1977.00500130053010. [DOI] [PubMed] [Google Scholar]
  25. Nelson H., Mandiyan S., Nelson N. Cloning of the human brain GABA transporter. FEBS Lett. 1990 Aug 20;269(1):181–184. doi: 10.1016/0014-5793(90)81149-i. [DOI] [PubMed] [Google Scholar]
  26. Pacholczyk T., Blakely R. D., Amara S. G. Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature. 1991 Mar 28;350(6316):350–354. doi: 10.1038/350350a0. [DOI] [PubMed] [Google Scholar]
  27. Pasinetti G. M., Lerner S. P., Johnson S. A., Morgan D. G., Telford N. A., Finch C. E. Chronic lesions differentially decrease tyrosine hydroxylase messenger RNA in dopaminergic neurons of the substantia nigra. Brain Res Mol Brain Res. 1989 May;5(3):203–209. doi: 10.1016/0169-328x(89)90036-3. [DOI] [PubMed] [Google Scholar]
  28. Perrett C. W., Marchbanks R. M., Whatley S. A. Characterisation of messenger RNA extracted post-mortem from the brains of schizophrenic, depressed and control subjects. J Neurol Neurosurg Psychiatry. 1988 Mar;51(3):325–331. doi: 10.1136/jnnp.51.3.325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Ritz M. C., Lamb R. J., Goldberg S. R., Kuhar M. J. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science. 1987 Sep 4;237(4819):1219–1223. doi: 10.1126/science.2820058. [DOI] [PubMed] [Google Scholar]
  30. Seeman P., Niznik H. B. Dopamine receptors and transporters in Parkinson's disease and schizophrenia. FASEB J. 1990 Jul;4(10):2737–2744. doi: 10.1096/fasebj.4.10.2197154. [DOI] [PubMed] [Google Scholar]
  31. Shimada S., Kitayama S., Lin C. L., Patel A., Nanthakumar E., Gregor P., Kuhar M., Uhl G. Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA. Science. 1991 Oct 25;254(5031):576–578. doi: 10.1126/science.1948034. [DOI] [PubMed] [Google Scholar]
  32. Willoughby J., Cowburn R. F., Hardy J. A., Glover V., Sandler M. 1-Methyl-4-phenylpyridinium uptake by human and rat striatal synaptosomes. J Neurochem. 1989 Feb;52(2):627–631. doi: 10.1111/j.1471-4159.1989.tb09165.x. [DOI] [PubMed] [Google Scholar]
  33. Wolf M. E., LeWitt P. A., Bannon M. J., Dragovic L. J., Kapatos G. Effect of aging on tyrosine hydroxylase protein content and the relative number of dopamine nerve terminals in human caudate. J Neurochem. 1991 Apr;56(4):1191–1200. doi: 10.1111/j.1471-4159.1991.tb11410.x. [DOI] [PubMed] [Google Scholar]
  34. Zelnik N., Angel I., Paul S. M., Kleinman J. E. Decreased density of human striatal dopamine uptake sites with age. Eur J Pharmacol. 1986 Jul 15;126(1-2):175–176. doi: 10.1016/0014-2999(86)90758-2. [DOI] [PubMed] [Google Scholar]
  35. Zigmond M. J., Stricker E. M. Animal models of parkinsonism using selective neurotoxins: clinical and basic implications. Int Rev Neurobiol. 1989;31:1–79. doi: 10.1016/s0074-7742(08)60277-9. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES